New triple-drug attack targets advanced lung cancer
NCT ID NCT07355205
First seen Jan 24, 2026 · Last updated Jun 12, 2026 · Updated 24 times
Summary
This study tests a combination of three drugs (nivolumab, ipilimumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this mix can keep the cancer from growing longer than current treatments. About 26 adults will take part, and the study will track side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.